Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10952432 | PMC |
| http://dx.doi.org/10.1111/nph.19344 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rubella virus assembly requirements and evolutionary relationships with novel rubiviruses.
mBio
October 2024
Department of Cell Biology, Albert Einstein College of Medicine, Bronx, New York, USA.
Unlabelled: Rubella virus (RuV) is an enveloped virus that usually causes mild disease in children, but can produce miscarriage or severe congenital birth defects. While in nature RuV only infects humans, the discovery of the related Ruhugu (RuhV) and Rustrela (RusV) viruses highlights the spillover potential of mammalian rubiviruses to humans. RuV buds into the Golgi, but its assembly and exit are not well understood.
View Article and Find Full Text PDFTRIM21 and Fc-engineered antibodies: decoding its complex antibody binding mode with implications for viral neutralization.
Front Immunol
June 2024
Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Munich, Roche Diagnostics GmbH, Penzberg, Germany.
Article Synopsis
- TRIM21 is a key player in the immune system, guiding antibody responses and affecting immune signaling.
- The study investigates how TRIM21 interacts with engineered antibodies to neutralize viruses, utilizing advanced analytical techniques.
- Findings suggest a unique dual binding mechanism that enhances TRIM21's ability to target viruses for degradation, offering insights for new antiviral therapies and strategies.
Bioinformatics-driven discovery of novel EGFR kinase inhibitors as anti-cancer therapeutics: In silico screening and in vitro evaluation.
PLoS One
April 2024
Department King Faisal Specialized Hospital and Research Center, Cell Therapy & Immunobiology, Riyadh, Saudi Arabia.
Epidermal growth factor receptor EGFR inhibitors are widely used as first line therapy for the treatment of non-small-cell lung cancer (NSCLC) in patients harboring EGFR mutation. However, the acquisition of a second-site mutation (T790 M) limited the efficacy and developed resistance. Therefore, discovery and development of specific drug target for this mutation is of urgent needs.
View Article and Find Full Text PDFIdentification of mIDH1 R132C/S280F Inhibitors from Natural Products by Integrated Molecular Docking, Pharmacophore Modeling and Molecular Dynamics Simulations.
Pharmaceuticals (Basel)
March 2024
College of Pharmacy, Shaanxi University of Chinese Medicine, Shiji Ave., Xi'an-Xianyang New Ecomic Zone, Xianyang712046, China.
Mutant isocitrate dehydrogenase 1 (mIDH1) is a common driving factor in acute myeloid leukemia (AML), with the R132 mutation accounting for a high proportion. The U.S.
View Article and Find Full Text PDFDiscovery of a second-site nia2 mutation in the background of multiple Arabidopsis PIF-related mutants containing the pif3-3 allele.
New Phytol
January 2024
Department of Biology, University of Oxford, Oxford, OX1 3RB, UK.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!